A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother transferred through the placenta protect newborns from birth
- Coverage achievable with two-week gap before early delivery
- Vaccination in third trimester still provides meaningful protection for infants
Compelling evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a comprehensive study undertaken in England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable data of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research gives healthcare professionals and expectant parents with confidence in the vaccine’s established performance across diverse populations and circumstances.
The results present a notable picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology captured actual clinical results rather than controlled laboratory conditions, providing practical evidence of how the vaccine functions when administered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for affected infants to breathe and feed effectively. Parents commonly see their babies fighting for breath, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst most newborns get better with clinical support, a modest yet notable group succumb from RSV complications yearly, making vaccination as prevention a essential public health imperative for defending the youngest and most vulnerable individuals in the population.
- RSV causes inflammation in lungs, leading to serious respiratory problems in infants
- Half of all infants catch the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of infants die from RSV related complications annually in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the importance of pregnant women getting their jab at the optimal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing is crucial for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery delivers approximately 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others continue working to increase awareness and availability of the jab. These regional differences reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows consistently strong protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to reach expectant mothers
- Inconsistencies across regions in immunisation take-up in different parts of England require targeted improvement
- Regional health providers adapting programmes to meet community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness provides tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% reduction in admissions means thousands of infants spared from serious illness. Parents no longer face the troubling prospect of watching their newborns labour to breathe or struggle to eat, symptoms that mark critical RSV illness. The vaccine has substantially transformed the picture of neonatal respiratory health, providing expectant mothers a preventative option to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection led to profound brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s support of the jab highlights the profound consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers in their late pregnancy, transforming what was once an predictable seasonal threat into a manageable health risk.